Coamoxiclav provides coverage for pathogens that cause acute otitis media (AOM), including beta lactamase producing strains. Most anaerobic bacteria found in AOM produce beta lactamases but are susceptible to co-amoxyclav. Co-amoxyclav achieves effective concentrations in the middle ear mucosa and effusions, has good tolerance, and efficacy rates as high as 94%.

1. Coamoxiclav